Altre lingue NetraMark Holdings Inc.

Azioni

AIAI

CA64119M1059

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 21:28:46 24/04/2024			Variaz. 5gg	Var. 1 gen.
0,305 ^CAD	0,00%		-9,63%	-12,86%

10/04	La soluzione clinica basata sull'Ai di Netramark identifica nuovi biomarcatori e sottopopolazioni di pazienti per il cancro al polmone e al colon	CI
04/04	NetraMark Holdings Inc. annuncia la nomina di Jeff Huntsman nel suo comitato consultivo strategico	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS	10/04
Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	10/04
NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS	05/04
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD	04/04
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	04/04
NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS	02/04
NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE	12/03
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	12/03
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	11/03
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING	11/03
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	11/03
NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024	29/02
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	27/02
NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS	27/02
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	27/02
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients	26/02
NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT DRIVERS OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS	26/02
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials	15/02
NETRAMARK TO PRESENT NEW DATA DEMONSTRATING THE POWER OF ITS AI BASED TECHNOLOGY TO DE-RISK NEUROLOGY CLINICAL TRIALS AT ISCTM ANNUAL MEETING	15/02
NETRAMARK ANNOUNCES LAUNCH OF THE NETRA AI LAB	12/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NetraMark Holdings Inc.

Azioni

AIAI

CA64119M1059

Altre lingue

Filtri